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Abstract 30 
Over the past ten years, standard diagnostics for cryptococcal meningitis in HIV-infected persons 31 
have evolved from culture, to India ink, to detection of cryptococcal antigen (CrAg) with the 32 
recent development and distribution of a point-of-care lateral flow assay. This assay is highly 33 
sensitive and specific in cerebrospinal fluid (CSF), but is also sensitive in the blood to detect 34 
CrAg prior to meningitis symptoms. CrAg screening in HIV-infected persons in the blood prior 35 
to development of fulminant meningitis, and preemptive treatment for CrAg-positive persons is 36 
recommended by the World Health Organization and many national HIV guidelines. Thus, CrAg 37 
testing is occurring more widely, especially in resource-limited laboratory settings. CrAg titer 38 
predicts meningitis and death, and could be used in the future to customize therapy according to 39 
burden of infection.  40 
 41 
Introduction 42 
Globally cryptococcal meningitis causes 15% of AIDS-related deaths, with an estimated 43 
181,100 deaths annually.(1) HIV-infected persons with advanced HIV disease are at highest risk 44 
of infection. While efforts are underway to increase access to antiretroviral therapy (ART) 45 
globally, persons who do not start, or who default ART remain at risk of cryptococcal 46 
meningitis.(2) The majority of cases of cryptococcal meningitis occur in sub-Saharan Africa 47 
where diagnostic facilities, access to optimal antifungal medications, and access to intensive 48 
hospital-based treatments are limited.(3) Thus, 6-month mortality from cryptococcal meningitis 49 
in hospital settings, despite standard of care antifungal therapy,  ranges from 40 to 60% in 50 
resource-limited settings.(2, 4) Over the last 10 years, drastic improvements in the development 51 
and distribution of a point-of-care lateral flow assay (LFA) for cryptococcal antigen (CrAg) has 52 
dramatically improved prevention efforts and diagnosis of this lethal infection.  53 
 54 
Diagnostics for cryptococcal meningitis 55 
Diagnosis of cryptococcal meningitis requires CSF culture, India ink or CrAg testing. 56 
Culture 57 
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CSF culture is considered the gold standard for diagnosis of cryptococcal meningitis. 58 
Unfortunately, diagnosis can take days, up to 1-2 weeks for definitive results. Thus, other 59 
diagnostic methods have been used to expedite diagnosis and treatment. In research settings, 60 
quantitative CSF cultures have been utilized which provide valuable clinical information.(5) 61 
These CSF quantitative cultures are easily performed in any microbiology laboratory. The simple 62 
technique uses 100 L input volume of CSF with five 1:10 serial dilutions in water, plating on 63 
Sabouraud dextrose agar, and then quantitative culture counting on the plate with the least 64 
growth.(5) Increasing quantitative culture burden is a risk factor for 2-week mortality with a 65 
~40% increase in odds of mortality per log10 CFU/mL CSF increase in Cryptococcus growth.(6) 66 
The change in quantitative culture growth with subsequent serial lumbar punctures gives 67 
clinicians valuable feedback on the rate of CSF Cryptococcus clearance, and when the CSF is 68 
likely to be sterile. 69 
India ink 70 
India ink microscopy has historically been a quick, low-resource method to detect 71 
Cryptococcus in the CSF.(7) The stain fills the background field, but is not taken up by the thick 72 
Cryptococcus capsule, forming a halo of light by which it can be visualized using a light 73 
microscope. While simple, and readily accessible in resource-limited settings, where the burden 74 
of cryptococcal infection is the greatest, unfortunately sensitivity is low, at 86% in expert hands, 75 
meaning 1 in 7 diagnoses are missed by India ink microscopy.(8) For persons presenting early in 76 
disease process with lower burden of infections, India ink’s sensitivity is only 42% when the 77 
CSF Cryptococcus colony forming units (CFUs) <1000 per mL of CSF.(8) CSF centrifugation 78 
can likely increase the sensitivity of microscopy; however, microscopy is less sensitive than 79 
testing for CrAg.(8) 80 
Cryptococcal Antigen 81 
CrAg can be identified using latex agglutination, which historically has a sensitivity and 82 
specificity of >99% in blood and CSF.(8)  More recent comparisons have reported sensitivities 83 
of 97-98% and specificities of 86-100% dependent on the specific manufacturer.(8) Results can 84 
be qualitative, or semi-quantitative with titers by 1:2 serial dilution. The latex agglutination 85 
detects polysaccharide antigens of the Cryptococcus capsule, but the process of performing the 86 
test requires testing in a laboratory environment, thus skilled laboratory workers, steady 87 
electricity, heat inactivation, cold-chain shipping, and refrigeration of reagents.(9) While feasible 88 
in high-income country laboratories, these requirements are frequently prohibitive where the 89 
majority of cryptococcal infection occurs. The major expense of the test in high-income country 90 
is laboratory labor. In low-income countries, the major expense is cold chain shipping and 91 
storage. Thus, clinicians historically have relied on India ink for diagnosis in low-income 92 
countries, despite the lower sensitivity.  Overall, CrAg latex agglutination is now an archaic test 93 
as latex agglutination is more expensive, more labor intensive, less sensitive, less specific, and 94 
requires cold-chain shipping/storage. (8) 95 
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The CrAg lateral flow assay (LFA), approved by the US Food and Drug Administration 96 
(FDA) in 2011 (Immy, Norman, OK), is an immunochromatographic dipstick assay that also 97 
detects antigen with qualitative or semi-quantitative results.(9) If CrAg is present in the drop of 98 
serum, plasma, or CSF sample, it will bind to the gold-conjugated, anti-cryptococcal antibodies 99 
on the test strip to cause a visible line. This FDA approved point-of-care dipstick test has 100 
changed the diagnostic landscape of cryptococcal meningitis, as it does not require laboratory 101 
infrastructure. Semi-skilled healthcare workers without laboratory training can perform this test 102 
in clinics, or at the patient bedside. No refrigeration is required, and results are available after 10 103 
minutes. Conversely, laboratory based CrAg testing using the latex agglutination takes 104 
approximately 5 hours from test ordering to availability of results in high-income settings.(8) 105 
In a large validation study in South Africa and Uganda, 832 HIV-infected persons 106 
underwent diagnostic testing for cryptococcal meningitis. The CrAg LFA performed best, with a 107 
sensitivity of 99.3% and specificity of 99.1% for CSF (Figure 1). CrAg testing by either latex 108 
agglutination or LFA was more sensitive than CSF culture, which has historically been 109 
considered the gold standard for diagnosis. Importantly the LFA identified 6 additional persons 110 
with cryptococcal meningitis that were not detected by any other means.(8)  111 
 In 2018, there are five manufacturers of CrAg LFAs. The first CrAg LFA by Immy is 112 
FDA-approved, (European Conformity) CE-marked in Europe, and has been used among 113 
hundreds of thousands of persons globally with large multi-site validation studies.  Three other 114 
CrAg LFAs have more limited validation data and none are FDA-approved. Second is the 115 
Biosynex CryptoPS (Biosynex, Paris, France), which is CE-marked in Europe. This CryptoPS is 116 
also marketed by Bio-Rad (Hercules, California, USA). To date, a single site validation study has 117 
been performed testing 186 serum/plasma and 23 CSF samples from Cameroon.(10)  In 118 
comparison to the FDA-approved Immy CrAg LFA, the CryptoPS LFA had 78% (11/14) 119 
sensitivity in serum, 92% (11/12) in plasma, and 100% (4 of 4) in CSF.(10) Specificity was 120 
excellent (100%) in all sample types.(10) In the initial validation study, among serum specimens 121 
positive by Immy CrAg LFA with Immy titers <1:100, only 2 of 5 were positive by Biosynex 122 
CrAg, missing titers positive at 1:10 and 1:20 dilution using the Immy LFA.(10)  More 123 
validation is needed among serum specimens with low titers and among CSF specimens.   124 
 A third test is the StrongStep CrAg (Liming Bio, China). In a two-site validation study in 125 
Uganda, 143 CSF and 167 plasma samples were tested in comparison to the Immy CrAg LFA 126 
and CSF culture.(11) The StrongStep performed well in CSF with 100% (101/101) sensitivity 127 
and 98% (41/42) specificity.(11)   However, the specificity was only 90% (101/112) in 128 
plasma.(11), with 98% sensitivity (54/55). The limited specificity of plasma in the setting of 129 
CrAg screening, and 9% CrAg prevalence rate equates to a positive predictive value of only 130 
50%.(11)   This test appears to be highly sensitive; however, there are substantial challenges with 131 
specificity.(11)      132 
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 Two other manufactured tests exist. The Dynamiker CrAg LFA and FungiXpert 133 
Cryptococcal Capsular Polysaccharide K-Set are manufactured in China. No published 134 
validation studies exist for either test, although Dynamiker has clinical validation studies 135 
ongoing in 2018. Neither test is approved in Europe or the United States. 136 
 CrAg testing in the blood to detect meningitis 137 
Management of cryptococcal meningitis is complex and resource-intensive. Specifically, 138 
persons with cryptococcal meningitis frequently have elevated intracranial pressure, caused by 139 
the large polysaccharide capsule of the cryptococcal organism plugging the arachnoid villa, and 140 
obstructing CSF outflow.(12) This elevated intracranial pressure is associated with increased 141 
mortality.(13) Therapeutic lumbar punctures are therefore needed to release this pressure and 142 
reduce mortality in persons with cryptococcal meningitis.(14, 15) In resource-limited settings, 143 
where access to lumbar punctures is difficult, combining the diagnostic lumbar puncture with the 144 
first therapeutic lumbar puncture would streamline care.(16) Thus, using peripheral blood for a 145 
rapid point-of-care diagnosis of cryptococcal meningitis, allows clinicians to remove large 146 
amounts of CSF and reduce intracranial pressure with the first lumbar puncture, as well as 147 
confirming the diagnosis. 148 
Performance of the CrAg LFA as a fingerstick point-of-care test has been evaluated in 149 
this context.(16) Specifically, for those with suspected meningitis, a point-of-care fingerstick 150 
CrAg LFA was performed prior to lumbar puncture and compared to subsequent plasma and 151 
CSF CrAg LFA. The positive predictive value of fingerstick LFA for the detection of CrAg in 152 
the blood was 100%, and 93% for cryptococcal meningitis (Figure 2). Those (7%) that had a 153 
positive fingerstick but negative CSF CrAg were found to have serum/plasma CrAg positive; 154 
thus these weren’t false positives, but actual cryptococcal infection the blood. Fingerstick had 155 
100% concordance with serum or plasma CrAg results, and 100% negative predictive value for 156 
excluding cryptococcal meningitis.  Fingerstick CrAg testing does have limitations in 157 
asymptomatic populations with low fungal burdens, where false negatives can occur in 158 
comparison to serum or plasma testing.(17) Pipetting fingerstick whole blood onto the LFA 159 
improves diagnostic performance over direct application of blood to the CrAg LFA sample 160 
pad.(17) 161 
Other Diagnostics 162 
Other available diagnostics in high-income country settings include PCR. The 163 
FilmArray® Meningitis/Encephalitis panel (Biofire, Salt Lake City, Utah) is a multiplex PCR 164 
assay that detects 14 meningitis-causing pathogens (bacteria, viruses, and fungi), including 165 
Cryptococcus. FilmArray PCR detected Cryptococcus in 96% (95%CI, 83%-99%) of CSF when 166 
there were >100 Cryptococcus colony forming units per mL of CSF, and specificity was 167 
100%.(18) The expense of multiplex-PCR does not make this an ideal cryptococcal-assay, but 168 
the multiplex component does make this very nice as an overall meningitis assay for common 169 
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causes of community-acquired meningitis.  As well, matrix-assisted laser desorption/ionization 170 
time-of-flight mass spectrometry (MALDI-TOF) has also been reported to detect Cryptococcus 171 
in clinical specimens.(19)  172 
 173 
CrAg-based screening for cryptococcal meningitis 174 
Early Cryptococcal Meningitis 175 
The majority of persons with cryptococcal meningitis present with signs and symptoms 176 
of meningitis (headache, neck stiffness, fever), and are found to have positive CSF CrAg with 177 
diagnostic lumbar punctures and peripheral blood CrAg through fingerstick or venipuncture. 178 
However, there is a population with symptoms of meningitis, who are negative for CSF CrAg 179 
and negative by CSF culture but CrAg positive in the blood.(20) In one cohort in Uganda, this 180 
represented 4.3% of those HIV-infected with suspected meningitis. This population (blood CrAg 181 
positive, symptoms of meningitis, but CSF CrAg negative) was presumed to have early 182 
cryptococcal CNS infection, and in-hospital mortality was 39%, which was similar to in-hospital 183 
mortality of those with fulminant cryptococcal meningitis (32%). Larger studies are needed to 184 
further characterize the natural history of this population.  185 
Cryptococcal Antigen Screening 186 
CrAg is detectable in blood weeks to months before onset of meningitis symptoms.(21) 187 
Prevalence of asymptomatic cryptococcal antigenemia varies from 1% to 15% among HIV-188 
infected persons with advanced HIV disease.(1, 22) In high-income countries the average 189 
prevalence of asymptomatic CrAg is 2.6%.(1) Asymptomatic CrAg positivity is an independent 190 
predictor of meningitis and death.(21, 23) Preemptively treating those with cryptococcal 191 
antigenemia with high dose fluconazole before symptoms of meningitis develop prevents 192 
mortality. This has been evaluated most rigorously in a randomized controlled trial of 2000 193 
persons with advanced HIV disease in sub Saharan Africa, that demonstrated a 28% survival 194 
benefit with CrAg screening and preemptive treatment, alongside adherence support (24). Given 195 
this clear survival benefit, the World Health Organization and numerous national HIV guidelines 196 
now recommend CrAg screening those with advanced HIV disease, and preemptively treating 197 
those CrAg+ with high dose fluconazole (25).  198 
CrAg Titer 199 
Both latex agglutination and CrAg LFA can be semi-quantified using titers. CrAg LFA 200 
titers are performing by the same serial dilution, and the titer is the last positive test before the 201 
dilution turns negative.  Titers across LFA manufacturers are not comparable, and even the titer 202 
between Immy latex-agglutination and Immy LFA; the median difference was 2.5-fold (IQR, 203 
1.25 to 5-fold) higher with the CrAg LFA.(8)  This difference in titer confirms the better 204 
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analytical sensitivity of the CrAg LFA over latex agglutination, but the titer difference is 205 
variable.  206 
CrAg titer is predictive of meningitis and death.(26-29)  Plasma CrAg titers <1:80 by 207 
Immy CrAg have an exceedingly low probability of meningitis. (26, 27)   As serum or plasma 208 
CrAg titers rise from 1:160 to 1:320 to 1:640, the probability of CSF involvement becomes 209 
increasingly probable.(27)  CrAg titers of >1:1280 have near universal central nervous system 210 
(CNS) involvement.(26, 27)  The Biosynex CrAg LFA provides a semi-quantification with both 211 
a low and high titer test lines.  The high CrAg titer band equates to approximately 1:1024 Immy 212 
CrAg LFA titer. 213 
There have been four published cohorts of asymptomatic CrAg+ persons investigating 214 
CrAg titer versus outcome, each relatively small.(26-29) We combined these cohorts to 215 
summarize the effect of CrAg titer on survival when preemptive fluconazole monotherapy is 216 
given to CrAg-positive persons. Of 415 records, 287 had plasma CrAg titers measured at time of 217 
starting fluconazole. Survival was measured for those with low CrAg titers (<1:160), medium 218 
titers (1:160 to 1:2560), and high titers (>1:2560). Survival decreased as the plasma CrAg titer 219 
increased (Log-rank P<0.0001) (Figure 3). Among asymptomatic CrAg+ persons, CrAg titers 220 
>1:160 are associated with increased mortality despite receiving fluconazole preemptive 221 
therapy.(28, 29)  222 
How to screen for CrAg 223 
There are two possible methods for implementing CrAg screening into laboratories. The 224 
first is reflexive laboratory testing. With this method, those with a CD4 cell count result <100 225 
cells/L would routinely have a CrAg performed on the remaining plasma specimen from the 226 
CD4 test. Thus, the ordering provider would not be responsible for initiating this test, but testing 227 
would occur via a laboratory protocol. The result would be presented with the CD4 lab test result 228 
with a brief explanation of what to do if the CrAg result is positive.  229 
The alternative is to depend on healthcare providers to order a CrAg test when a CD4 lab 230 
value returns <100 cells/L. While a seemingly simple task, in settings that are already 231 
overburdened and understaffed, asking providers to remember to order this lab test has proved 232 
challenging. In one South African evaluation, only 27% of eligible persons were CrAg screened 233 
using a provider-initiated approach (30). Conversely, with reflex laboratory testing >95% of 234 
eligible persons were screened (30).  Additionally, by having a provider order the test, there is a 235 
delay in testing. A new CrAg positive result in an untreated patient is a critical laboratory result, 236 
requiring urgent action to prevent progression to meningitis and death.  237 
The difficulties with laboratory based screening are that there is often a delay between 238 
receipt of the lab result and bringing the patient back to the clinic for results and potential 239 
treatment. Conversely with provider initiated screening, there is less uptake of initial screening, 240 
but if done in the clinic room with the patient, the results are potentially available in 10 minutes, 241 
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and the patient can initiate therapy immediately, if needed. In the United States, CrAg testing is 242 
not a U.S. Clinical Laboratory Improvement Amendments (CLIA)-waived test, so provider 243 
point-of-care testing would not be allowable. In most high prevalence settings where CrAg 244 
screening occurs, a reflexive laboratory-based approach has been adopted.  South Africa 245 
performs reflexive CrAg screening at national laboratories where CD4 testing is performed.  246 
 247 
Future Implications & Conclusions 248 
Given the importance of CrAg titer in predicting meningitis and/or death, CrAg titer will 249 
likely be used in the future to customize therapy both for prevention and treatment of 250 
cryptococcal meningitis. For example, if someone is found to be asymptomatic with a low CrAg 251 
titer (<1:160), they could be treated with fluconazole preemptive therapy, per current standard of 252 
care. However, given the high mortality despite high dose fluconazole in asymptomatic persons 253 
with a high CrAg titer, more intensive therapies should be evaluated to improve survival. Such 254 
therapies may include liposomal amphotericin and/or flucytosine. It is also possible that in those 255 
with fulminant meningitis, those with high titers may benefit from longer duration of therapy 256 
compared to those with low titers. Thus, titer will likely play a significant role in the 257 
management of cryptococcal infection, both in low-income areas and in the high-income 258 
settings. Infectious Diseases Society of America (IDSA) guidelines currently recommend 4 259 
weeks of amphotericin for those with cryptococcal meningitis without HIV infection. This 260 
recommendation is based on no empiric data. Evaluation of how to shorten duration of therapy 261 
based on burden of infection (i.e. titer or quantitative culture) would be novel, and would spare 262 
patients exposure to toxic antifungal therapy.  263 
 In the last 20 years, cryptococcal testing has progressed from culture, which takes days 264 
for results, thereby clinically unhelpful with initial diagnosis, to India Ink, which is technically 265 
easy and quick, but with poor sensitivity, to a highly sensitive and specific point-of-care lateral 266 
flow assay that can be done at the patient bedside for rapid diagnosis. This evolution has greatly 267 
improved meningitis diagnosis and expedited initiation of effective treatment. Furthermore, the 268 
cost of $2.50 to $3.00 for the Immy CrAg LFA in resource-limited settings has made screening 269 
for cryptococcal infection a cost-effective strategy to prevent meningitis and death. (9, 31) CrAg 270 
titer predicts meningitis and death. Future areas of research include evaluation of customized 271 
therapy according to titer in persons with cryptococcal infection. The evolution of cryptococcal 272 
diagnostics highlights the enormous impact of point-of-care diagnostics in enhancing medical 273 
care and public health programs.  274 
 275 
  276 
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Figure 1: Venn Diagram of Distribution of CSF Diagnostic Testing in Uganda and South Africa 1 
during 2006-2012 (n=832).(8) 2 
 3 
Figure 2. Venn Diagram of the Distribution of Positivity by Blood CrAg, CSF CrAg, and CSF 4 
Culture (16). 5 
 6 
Figure 3. Survival by CrAg titer in 287 Asymptomatic HIV-infected Persons with Cryptococcal 7 
Antigenemia in four cohorts in Ethiopia, South Africa, Tanzania, and Uganda.(26, 27, 29, 32)  8 
 9 
 10 
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